J9359 HCPCS Level II code: Injection, loncastuximab tesirine-lpyl, 0.075 mg
J9359 is the HCPCS code for “Injection, loncastuximab tesirine-lpyl, 0.075 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J9359Injection, loncastuximab tesirine-lpyl, 0.075 mg
Short description: Inj lon tesirin-lpyl 0.075mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J9359 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Apr 1, 2022
Where J9359 sits
- 1J codesDrugs administered other than orally
- 2Active code J9359Injection, loncastuximab tesirine-lpyl, 0.075 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J9359 mean?
J9359 is the HCPCS code for “Injection, loncastuximab tesirine-lpyl, 0.075 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J9359?
CMS lists J9359’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J9359
All J codesJ9353Injection, margetuximab-cmkb, 5 mgJ9354Injection, ado-trastuzumab emtansine, 1 mgJ9355Injection, trastuzumab, excludes biosimilar, 10 mgJ9356Injection, trastuzumab, 10 mg and hyaluronidase-oyskJ9357Injection, valrubicin, intravesical, 200 mgJ9358Injection, fam-trastuzumab deruxtecan-nxki, 1 mgJ9360Injection, vinblastine sulfate, 1 mgJ9361Injection, efbemalenograstim alfa-vuxw, 0.5 mgJ9362Injection, trabectedin, 0.01 mgJ9370Vincristine sulfate, 1 mgJ9371Injection, vincristine sulfate liposome, 1 mgJ9376Injection, pozelimab-bbfg, 1 mg